Common Stock

Common Stock

Common Stock

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

wasnington,	D.C.	20549	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPRO	OVAL
OMB Number:	3235-0287
Estimated average burd	den
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Williams Kristen Marie				2. Issuer Name and Ticker or Trading Symbol Pacira BioSciences, Inc. [PCRX]							Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner			
(Last) C/O PACIRA BI 5 SYLVAN WAY	•	(Middle)	,	3. Date of Earliest Transaction (Month/Day/Year) 04/13/2021							Officer (give title Other (specify below) below) Chief Administrative Officer			
(Street) PARSIPPANY NJ 07054 (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Benefit								Line) X	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day			ion	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)	ction	4. Securities Disposed Of	Acquired	(A) or	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock			04/13/2	021		M ⁽¹⁾		2,500	A	\$32.35	27,387	D		
Common Stock			04/13/2	021		M ⁽¹⁾		4,125	A	\$44.2	31,512	D		
Common Stock			04/13/2	021		M ⁽¹⁾		8,859	Α	\$38.35	40,371	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

 $M^{(1)}$

s(1)

 $S^{(1)}$

04/13/2021

04/13/2021

04/13/2021

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of Deri Sec Acq (A) (Disp of (I	osed 0) tr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$32.35	04/13/2021		М			2,500	(4)	12/07/2026	Common Stock	2,500	\$0.00	0	D	
Stock Option (Right to Buy)	\$44.2	04/13/2021		М			4,125	(4)	06/14/2027	Common Stock	4,125	\$0.00	1,375	D	
Stock Option (Right to Buy)	\$38.35	04/13/2021		М			8,859	(5)	06/13/2028	Common Stock	8,859	\$0.00	14,765	D	
Stock Option (Right to Buy)	\$43.54	04/13/2021		М			6,339	(5)	06/05/2029	Common Stock	6,339	\$0.00	19,010	D	

Explanation of Responses:

- 1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$66.96 to \$67.95, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$67.96 to \$68.41, inclusive.
- 4. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date.
- 5. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Remarks:

/s/ Kristen Williams

Α

D

D

\$43.54

\$66.4(2)

\$68.11(3)

46,710

31,917

24,887

D

D

D

6,339

14.793

7,030

04/15/2021

Date

** Signature of Reporting Person

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.